Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda

byiShook Opinion
Sep 9, 2024 - 09:00

Share

Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda. The post Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda appeared first on Investor's Business Daily.

Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda.

The post Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda appeared first on Investor's Business Daily.